Avidity Partners 13F holdings, Q1 2024
Holdings as of March 31, 2024 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 87 US equity positions worth $2.8bn in its Q1 2024 13F filing. The largest position was FUSION PHARMACEUTICALS INC at 4.9% of the reported book, followed by BSX and ARVN. Against the Q4 2023 filing, it opened 11 new positions, added to 10 and reduced 24 among the top 50 holdings.
What did Avidity Partners own in Q1 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2023 |
|---|---|---|---|---|---|---|---|
| 1 | FUSION PHARMACEUTICALS INC | 4.9% | $138.6m | 6,500,328 | 0% | held | |
| 2 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 4.8% | $134.0m | 1,956,000 | 3% | added |
| 3 | ARVN ARVINAS INC | Healthcare | 4.4% | $123.2m | 2,985,190 | 0% | held |
| 4 | ISRG INTUITIVE SURGICAL INC | Healthcare | 3.2% | $90.2m | 226,000 | 166% | added |
| 5 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.9% | $81.5m | 2,717,554 | 123% | added |
| 6 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 2.8% | $79.6m | 1,005,000 | -13% | reduced |
| 7 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.6% | $74.0m | 536,500 | -18% | reduced |
| 8 | NTRA NATERA INC | Healthcare | 2.6% | $73.5m | 803,300 | -28% | reduced |
| 9 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 2.5% | $70.3m | 584,000 | 19% | added |
| 10 | AVTR AVANTOR INC | Healthcare | 2.4% | $68.9m | 2,695,000 | 27% | added |
| 11 | CI THE CIGNA GROUP | Healthcare | 2.4% | $67.0m | 184,500 | – | new |
| 12 | MRK MERCK & CO INC | Healthcare | 2.4% | $66.2m | 502,000 | – | new |
| 13 | REGN REGENERON PHARMACEUTICALS | Healthcare | 2.3% | $65.4m | 68,000 | 0% | held |
| 14 | CGON CG ONCOLOGY INC | Healthcare | 2.3% | $63.9m | 1,454,765 | – | new |
| 15 | ILMN ILLUMINA INC | Healthcare | 2.3% | $63.7m | 464,100 | – | new |
| 16 | THC TENET HEALTHCARE CORP | Healthcare | 2.2% | $63.2m | 601,000 | -31% | reduced |
| 17 | ALGN ALIGN TECHNOLOGY INC | Healthcare | 2.2% | $62.0m | 189,000 | 21% | added |
| 18 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.0% | $57.4m | 2,412,500 | -39% | reduced |
| 19 | LLY ELI LILLY & CO | Healthcare | 1.9% | $54.5m | 70,000 | -18% | reduced |
| 20 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 1.8% | $49.8m | 217,000 | -9% | reduced |
| 21 | ALPINE IMMUNE SCIENCES INC | 1.7% | $46.6m | 1,174,700 | – | new | |
| 22 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.5% | $43.6m | 933,500 | 11% | added |
| 23 | CVS CVS HEALTH CORP | Healthcare | 1.5% | $43.5m | 545,000 | -26% | reduced |
| 24 | SGRY SURGERY PARTNERS INC | Healthcare | 1.5% | $43.1m | 1,445,000 | 24% | added |
| 25 | INTRA-CELLULAR THERAPIES INC | 1.5% | $41.5m | 600,000 | -15% | reduced | |
| 26 | ABBV ABBVIE INC | Healthcare | 1.5% | $41.3m | 227,000 | -20% | reduced |
| 27 | 2655787D BLUEPRINT MEDICINES CORP | 1.4% | $40.4m | 426,000 | -31% | reduced | |
| 28 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.3% | $37.5m | 668,300 | -2% | reduced |
| 29 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.3% | $37.0m | 864,000 | -20% | reduced |
| 30 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.3% | $36.3m | 243,000 | – | new |
| 31 | DHR DANAHER CORPORATION | Healthcare | 1.3% | $35.9m | 143,800 | -50% | reduced |
| 32 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.2% | $35.1m | 799,700 | -47% | reduced |
| 33 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.2% | $34.4m | 431,000 | -6% | reduced |
| 34 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.1% | $30.6m | 710,000 | -13% | reduced |
| 35 | LNTH LANTHEUS HLDGS INC | Healthcare | 1.1% | $29.9m | 480,000 | 26% | added |
| 36 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 1.1% | $29.7m | 5,785,352 | -9% | reduced |
| 37 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 1.0% | $28.7m | 1,142,850 | 0% | held |
| 38 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.0% | $27.6m | 1,025,000 | -40% | reduced |
| 39 | RGNX REGENXBIO INC | Healthcare | 1.0% | $27.4m | 1,300,064 | – | new |
| 40 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.9% | $25.6m | 384,893 | – | new |
| 41 | NMRA NEUMORA THERAPEUTICS INC. | Healthcare | 0.9% | $24.8m | 1,800,000 | -10% | reduced |
| 42 | DXCM DEXCOM INC | Healthcare | 0.9% | $24.5m | 176,900 | – | new |
| 43 | NGNE NEUROGENE INC | 0.8% | $23.7m | 465,237 | -0% | held | |
| 44 | JASPER THERAPEUTICS INC | 0.8% | $22.3m | 760,000 | – | new | |
| 45 | IMNM IMMUNOME INC | Healthcare | 0.8% | $21.6m | 873,891 | -34% | reduced |
| 46 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 0.8% | $21.3m | 36,600 | -80% | reduced |
| 47 | GKOS GLAUKOS CORP | Healthcare | 0.8% | $21.1m | 224,000 | – | new |
| 48 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.7% | $20.5m | 635,000 | 958% | added |
| 49 | PCVX VAXCYTE INC | Healthcare | 0.7% | $19.4m | 284,000 | -50% | reduced |
| 50 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.7% | $18.6m | 286,400 | -5% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.